Acute onset of fingolimod-associated macular edema
Purpose: Fingolimod is among the first oral disease-modifying agents for the treatment of relapsing-remitting multiple sclerosis (MS). Despite its favorable safety profile, fingolimod may cause macular edema, a significant adverse event, which occurs within the first 4 months of therapy. Macular ede...
Gardado en:
| Principais autores: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Elsevier
2016-12-01
|
| Series: | American Journal of Ophthalmology Case Reports |
| Assuntos: | |
| Acceso en liña: | http://www.sciencedirect.com/science/article/pii/S2451993615300323 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|